Brief Description

SB 939 is a potent pan-HDAC inhibitor with IC50 of 40-140 nM with exception for HDAC6; has no activity against the class III isoenzyme SIRT I.
IC50 Value: 49 nM(HDAC1); 43 nM(HDAC3); 56 nM(HDAC4); 47 nM(HDAC5); 70 nM(HDAC9); 40 nM(HDAC10)
Target: HDACs
SB 939 is an orally bioavailable, small-molecule histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Pracinostat (SB939) inhibits HDACs, which may result in the accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; the tumor suppressor protein-mediated inhibition of tumor cell division; and, finally, the induction of tumor cell apoptosis. SB 939 may possess improved metabolic, pharmacokinetic and pharmacological properties compared to other HDAC inhibitors.

Solubility

DMSO ≥70mg/mL; Water <1.2mg/mL; Ethanol ≥70mg/mL

Melting point

Boiling point

Density

Formula Weight:

Flash point

Storage conditions

Store at -20°C 2 years

Appearance:

White to off-white solid